-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The company has been awarded the title of “Provincial Model Enterprise for Integrity.”
Category:
发布时间：2018-01-04
【概要描述】
On September 27, the Hebei Province Integrity Enterprise Selection was announced, with our company once again making the list, thereby fully demonstrating our strong capabilities in strengthening integrity system development, innovating integrity management practices, establishing and improving an internal credit cultivation system, and continuously advancing brand building.
On September 27, the Hebei Province Integrity Enterprise Selection Event announced its results, with our company once again making the list, thereby fully demonstrating our strong capabilities in strengthening integrity system development, innovating integrity management practices, establishing and improving an internal credit cultivation system, and continuously advancing brand building.
Recently, the Office of the Hebei Provincial Committee for the Selection of Trustworthy Enterprises, in collaboration with the Hebei Provincial Entrepreneurs Association and relevant provincial authorities, jointly organized the “Hebei Provincial Trustworthy Enterprise” selection and recognition campaign. For many years, the company has steadfastly upheld the corporate philosophy of “winning public trust through quality and putting integrity at the core,” using quality as the foundation for building trust. In 1985, it was among the first in the national industry to put forward the quality credo: “One bottle of intravenous solution can mean life or death; every bottle of intravenous solution is for the people.” Sinyao integrates corporate responsibility and a culture of quality into every stage of the production process, regarding the manufacture of high-quality medicines that consumers can trust as the focal point for embodying this quality culture, and striving to ensure that its products stand up to market scrutiny at all times.
Honesty and trustworthiness are integral to the company’s fulfillment of its social responsibilities and to building its brand. In recent years, the company has boldly shouldered its social responsibilities and diligently carried them out, thereby achieving more robust corporate development. The company deeply recognizes that strengthening corporate social responsibility is just as important as enhancing its corporate image and brand; only by upholding honesty and trustworthiness can it ensure that its products are genuine and reasonably priced. In June 2017, the company was honored by the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce as the “Law-Abiding and Trustworthy Enterprise” for 2016, in recognition of its outstanding performance in the pharmaceutical sector and its commitment to ethical business practices.
The company actively champions and implements the business philosophy of “green pharmaceuticals and circular development,” accelerating transformation and upgrading. It focuses on intensive and economical land use and enhancing the comprehensive utilization of land resources, thereby maximizing both economic and social benefits from limited land assets. The company also places great emphasis on the construction of energy-saving and emission-reduction projects, firmly committing to sustainable development. By leveraging information technology and technological innovation, it strengthens energy information management and promotes energy conservation and emission reduction across the enterprise. In 2017, the company’s integration of informatization and industrialization management system was certified, and that same year, it was included in the Ministry of Industry and Information Technology’s first batch of green manufacturing demonstration enterprises.
Treat employees with sincerity and foster a harmonious workplace. To ensure the company’s long-term development and fully harness the enthusiasm and creativity of all staff, we steadfastly believe that only people-centered management can truly unlock human potential—and it is this approach that has consistently driven one remarkable achievement after another.
Throughout its operations, the company places great emphasis on meeting the cultural needs of its employees and meticulously organizes a series of cultural and sports activities. In addition, in light of actual production conditions, the company rewards those who submit rationalization proposals, implement minor improvements and innovations, and excel in labor competitions. By recognizing and rewarding excellence and encouraging creativity, the company has cultivated new momentum for innovative development.
Keywords:
Next page
Next page:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091